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The role of microtubule (MT) dysfunction in Parkinson’s disease is emerging. It is still unknown whether it
is a cause or a consequence of neurodegeneration. Our objective was to assess whether alterations of MT
stability precede or follow axonal transport impairment and neurite degeneration in experimental
parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57Bl mice. MPTP
induced a time- and dose-dependent increase in fibres with altered mitochondria distribution, and early
changes in cytoskeletal proteins and MT stability. Indeed, we observed significant increases in
neuron-specific bIII tubulin and enrichment of deTyr tubulin in dopaminergic neurons. Finally, we showed
that repeated daily administrations of the MT stabilizer Epothilone D rescued MT defects and attenuated
nigrostriatal degeneration induced by MPTP. These data suggest that alteration ofMTs is an early event
specifically associated with dopaminergic neuron degeneration. Pharmacological stabilization of MTs may
be a viable strategy for the management of parkinsonism.
A
xonogenesis and dendritogenesis, which are essential for the normal development of neurons, rely on the
coordinated organization and dynamics of the actin and microtubule (MT) cytoskeleton. MTs are poly-
mers built up by a/b tubulin heterodimers, characterized by an intrinsic resistance to bending and
compression1. They are capable of switching between phases of slow growth and of rapid depolymerization2,
features implicated in generating pushing and pulling forces within cells3. During neuronal differentiation, MTs
are highly dynamic and ensure outgrowth and branching4. Inmature neurons,MT stability increases5. The proper
control of MT dynamics is essential for many neuronal activities, such as synaptic remodelling6, and both MT
stability and neuronal functions are regulated through tubulin posttranslational modifications (PTMs)7.
Axon degeneration is a hallmark of neurodegenerative disorders and often precedes the onset of symptoms.
Axonal destruction is an active process rather than a passive event8. Although little is known about the mechan-
isms involved, a growing body of evidence suggests a primary role of theMT system. In fact, MT fragmentation is
the first detectable event during Wallerian degeneration9, and disorganized and bent MTs accompany the
formation of retraction bulbs10 and axonal retraction11.
Parkinson’s disease (PD) is the most common motor neurodegenerative disorder and each symptom depends
on the reduction in dopamine (DA) levels in the striatum. Degeneration of nigrostriatal dopaminergic synaptic
terminals precedes the death of dopaminergic neurons in the substantia nigra12.Many PD-linked proteins, such as
a-synuclein13, parkin14, and leucine rich repeat kinase 215, modulate the stability of MTs, highlighting the crucial
role ofMTs during PDprogression. Furthermore, PD is the only neurodegenerative disorder that is clearly related
to environmental toxins, such as 1-methyl-4-phenylpiridinium (MPP1) or rotenone12, which both destabilize
MTs16,17. Alterations in MT stability precede axonal transport impairment and neurite degeneration in MPP1-
exposed PC12 cells18, suggesting that MT dysfunction plays an important role in mediating the toxicity of these
compounds. It is noteworthy that both prophylactic and interventional treatments with the MT-stabilizer
Epothilone D (EpoD), which is able to pass the blood-brain barrier, improve axonal MT density, reduce axonal
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dystrophy and alleviate cognitive deficits in transgenicmousemodels
of tauopathies19,20. It has also been shown that the dynamicity ofMTs
is increased in tau transgenic mice and that treatment with EpoD
restores MT dynamics to baseline levels and exerts beneficial effects
on behavior, tau pathology and neurodegeneration21.
We now show that C57Bl mice treated with 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) express early alterations of a-
tubulin PTMs specifically in dopaminergic neurons, and that
systemic injections of EpoD rescue MT defects and attenuate nigros-
triatal degeneration in mice with parkinsonian symptoms produced
by exposure to the toxin MPTP.
Results
Treatment paradigm underlines early alterations. One single dose
ofMPTP (30 mg/kg, i.p.) induced about 50–60% reduction in striatal
DA levels 7 days later in C57Bl mice, as expected22. To highlight very
early alterations, mice were treated either with a single dose (30 mg/
kg, i.p.) or with a cumulative dose (60 mg/kg) of MPTP, and sacri-
ficed 12 or 72 h later. Biochemical analyses showed that MPTP
induced a significant reduction in striatal DA and its metabolites,
a sign of ongoing neurodegeneration (Fig. 1a). Western Blotting
analysis showed that TH, the rate-limiting enzyme of DA biosyn-
thesis, was decreased in the striatum and substantia nigra only with
the highest dose of MPTP (Fig. 1b,c). Ara and colleagues23 showed
that MPTP induces early inactivation of the enzyme, followed by
reduction in TH levels; therefore, mice treated with the low dose of
MPTP (30 mg/kg), which do not show any changes in TH levels,
can be considered to be in an early phase of neurodegeneration,
and may be used to uncover very early alterations in experimental
parkinsonism.
MPTP causes axonal transport impairment in dopaminergic
fibres. Mitochondria, as well the other organelles, accumulate into
varicosities when axonal transport is impaired24, and there is
evidence that MPP1 interferes with this process18,25,26. Therefore, to
assess the status of axonal transport in MPTP-treated mice, we
evaluated mitochondria distribution within dopaminergic fibres by
performing a double immunohistochemical analysis in sagittal
sections of TH and voltage-dependent anion channel (VDAC)-
porin, a structural protein of the mitochondrial pore. We observed
dopaminergic fibres with a homogeneous distribution of mito-
chondria and fibres showing sparse or accumulated mitochondria
(Fig. 2a, arrowheads). It is noteworthy that only mice treated with
MPTP and killed 72 h later showed empty fibres (Fig. 2a, arrow),
as the mitochondria had been kept out of neuronal processes.
Quantification of the different types of fibres (Fig. 2b), showed a
time- and dose-dependent increase in fibres with altered mito-
chondria distribution in treated mice. No significant differences
were observed between control mice and mice treated for 12 h
with 30 mg/kg MPTP. These data show that MPTP affects axonal
transport in vivo.
Figure 1 | Treatment paradigm underlines early alterations. (a) Biochemical analyses of striatal dopamine, DOPAC and HVA levels in C57Bl mice
injected with saline or MPTP (30 mg/kg, i.p., single injection or 20 mg/kg, i.p., 3 3, 2 h apart) and killed 12 or 72 hours later (mean 6 S.E.M., n 5 8–10
mice per group). *P , 0.05; one-way ANOVA, Dunnett post hoc versus saline-injected mice. (b) Immunoblot of TH levels in lysates of the corpus
striatum and substantia nigra of mice injected with saline or MPTP as in a. (c) Densitometric analyses of immunoblot reported in b (mean 6 S.E.M.,
n 5 8–10 mice per group). *P , 0.05; one-way ANOVA, Dunnett post hoc test versus saline-injected mice. hpi 5 hours post last injection of MPTP.
www.nature.com/scientificreports
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MPTP increases the neuron-specific bIII tubulin isotype. Axonal
transport defects could be related to alterations of cytoskeletal
proteins and molecular motors. Thus, we evaluated levels of actin,
a- and b-tubulin, and the neuron-specific bIII tubulin isotype.
Western blotting and densitometric analyses showed that levels of
actin and a/b tubulin were unchanged in the striatum (Fig. 3a,b) and
substantia nigra (Fig. 3c,d) of MPTP-treated mice. b-tubulin was
significantly reduced in the striatum of mice treated with MPTP
(30 mg/kg) and killed 72 h later (Fig. 3a,b). The specific change in
b-tubulin is not surprising, because Chung and colleagues27 already
showed differential variations in a- and b-tubulin monomers in a rat
model of synucleinopathy, and we have recently found significant
enrichment of b-tubulin in the fibroblasts of PD patients carrying
parkin mutations28. On the other hand, the neuron-specific bIII
tubulin isotype was significantly increased by MPTP treatment in
both striatum and substantia nigra, although at different time points
Figure 2 | MPTP causes axonal transport impairment. (a) Mask projections of sagittal sections of the nigrostriatal pathway in mice injected with saline
or MPTP as in Fig. 1, showing the distribution of mitochondria (white spots) inside dopaminergic fibres (red). Arrowheads indicate mitochondria
accumulations and arrow highlights an empty fibre. Scale bar5 20 mm. (b) Percentage of fibres displaying a homogeneous distribution ofmitochondria,
fibres showing dispersed or accumulated mitochondria or empty fibres. hpi 5 hours post last injection of MPTP (mean 6 S.E.M., n 5 9 sections from 3
different mice per group). *P , 0.05; x2 test versus saline-injected mice.
Figure 3 | MPTP treatment increases the bIII tubulin isotype. (a) Immunoblots of actin, a-tubulin, b-tubulin and bIII tubulin in lysates of striatum of
mice treated as in Fig. 1. (b) Densitometric analyses of immunoblot reported in a (mean 6 S.E.M., n 5 4–6 individuals per group). *P , 0.05;
one-way ANOVA, Dunnett post hoc test versus saline-injected mice. (c) Immunoblot of actin, a-tubulin, b-tubulin and bIII tubulin in lysates of
substantia nigra of mice treated as in Fig. 1. (d) Densitometric analyses of immunoblot reported in c (mean 6 S.E.M., n 5 4–6 individuals per group).
*P , 0.05; one-way ANOVA, Dunnett post hoc test versus saline-injected mice. hpi 5 hours post last injection of MPTP.
www.nature.com/scientificreports
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(Fig. 3). Levels of kinesin and dynein, responsible for MT-dependent
anterograde and retrograde axonal transport, respectively29, were not
affected by MPTP treatment (Supplementary Fig. S1), suggesting
that axonal transport defects may be due to alternative factors.
MPTP specifically affects MT stability in dopaminergic neurons.
a-tubulin PTMs are usually used as markers of MTs with different
stability, being tyrosinated (Tyr) MTs the most dynamic, and acety-
lated (Ac) or detyrosinated (deTyr) MTs the most stable pools7.
Recently, it has been shown that a-tubulin PTMs are directly
linked to neurodegeneration in mice30 and MPP1 affects a-tubulin
PTMs in PC12 cells18. Therefore, we evaluated MT stability in the
striatum (Fig. 4) and substantia nigra (Fig. 5) of MPTP-treated mice,
as well as along their nigrostriatal pathway (Supplementary Fig. S2).
Biochemical analyses showed the enrichment of deTyr tubulin in
striatum (Fig. 4a,b), which was detectable already 12 h after the
injection of the lowest dose of MPTP, and a later increase in both
Tyr and Ac tubulins. Confocal analyses and the evaluation of Man-
ders’ coefficients (M1 and M2, reported in Table 1 and Supplemen-
tary Table S1, respectively), which are good indicators of relative
signal distribution31, showed that changes in the levels of tubulin
PTMs were located in dopaminergic terminals. In fact, we obser-
ved an increased co-localization between deTyr or Ac Tub and TH
signals (Fig. 4c) and significant elevation in M1 parameter (Table 1).
On the other hand, the significant decrease in the M1 parameter
(Table 1) demonstrated that the enrichment of Tyr tubulin was
associated with neurons residing in the striatum.
Western blotting analysis performed on substantia nigra lysates
(Fig. 5a, b), revealed a significant decrease in Tyr tubulin in MPTP-
treated mice, suggesting that the dynamic MT pool was reduced, as
we already showed in cultured cells18. On the other hand, MPTP
induced a significant enrichment of deTyr tubulin in mice treated
with MPTP (60 mg/kg) and killed 12 h later, suggesting an increase
in stable MTs, which mirrors the changes observed in the striatum.
Confocal analyses showed that a-tubulin PTM changes occurred in
dopaminergic cell soma (Fig. 5c), and the quantification of fluor-
escence intensity within single cells (Supplementary Table S2)
showed that alterations of MT stability are higher in dopaminergic
neurons. Indeed, we observed a significant reduction in Tyr tubulin
and an early increase in deTyr and Ac tubulins that resulted in the
decrease of stable MTs.
Finally, as a-tubulin PTMs influence axonal transport32,33, we eval-
uated potential changes within dopaminergic fibres by confocal
microscopy (Supplementary Fig. S2). Besides the slight changes
observed in Tyr and Ac tubulin content, the overall result we
obtained is an early increase in deTyr tubulin, in line with the mod-
ifications of this subset of stable MTs in the striatum and substantia
nigra of MPTP-treated mice, which could be responsible for the
impairment of axonal transport, as already suggested18. Taken
together, these results show that MPTP affects MT stability in vivo,
and that the alteration of a-tubulin PTMs is an early event specif-
ically associated with dopaminergic neurons.
Stabilization of MT attenuates MPTP-induced neurodegener-
ation. To test the hypothesis that stabilization of MT is able to
exert a neuroprotective effect in experimental parkinsonism, we
used the classical model induced by MPTP. C57 Black mice were
challenged with a single dose of MPTP (30 mg/kg, i.p.), which led, 7
days later, to about 50% reduction in striatal DA levels. Similar
reductions were found in the striatal levels of DOPAC and HVA,
although changes in DOPAC and HVA levels were variable in
different experiments (Fig. 6a). Reductions in DA were not
affected in mice systemically injected with 1 or 3 mg/kg, i.p., of
EpoD 30 min prior to MPTP (Fig. 6a). Repeated treatment with
EpoD (1 mg/kg, i.p.), injected 30 min prior to MPTP and then for
the following 4 days once a day, induced substantial attenuation of
MPTP-induced striatal DA reduction (Fig. 6b). Note that, for
unknown reasons, MPTP toxicity was greater in control animals
injected with DMSO alone. Neuroprotection by repeated injections
of EpoD was confirmed by stereological counts of TH-positive
neurons in the pars compacta of substantia nigra (Fig. 6c,d). To
assess the effects of EpoD on motor activity, mice were treated i.p.
with EpoD alone (3 mg/kg, every day for four days) or 30 min prior
MPTP and then every day for four days. EpoD did not affect the
Figure 4 | MPTP affects MT stability in dopaminergic terminals. (a) Immunoblot of levels of tyrosinated tubulin (Tyr Tub), detyrosinated tubulin
(deTyr Tub) and acetylated tubulin (Ac Tub) in lysates of striatum of mice treated as in Fig. 1. (b) Densitometric analyses of immunoblot reported in a
(mean 6 S.E.M., n 5 4–6 mice per group). For the quantitation, values of each a-tubulin PTMwere normalized on the level of a-tubulin (a Tub) of the
relative sample. *P, 0.05; one-way ANOVA,Dunnett post hoc test versus saline-injectedmice. (c) Confocal images of striatumofmice treated as in Fig. 1.
Green represents TH staining and red signals the various tubulin PTMs. Scale bar 5 50 mm. hpi 5 hours post last injection of MPTP.
www.nature.com/scientificreports
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motor performance on the rotarod test by itself (not shown). At the
doses of MPTP used, we did not observe any modification of motor
performance and EpoD treatment did not modify the motor coor-
dination at the rotarod test (not shown). We also monitored general
health conditions of mice treated with EpoD and MPTP1EpoD.
Both fur and body weight were not affected by EpoD or MPTP1
EpoD treatments.
To verify that the neuprotective effect of EpoD was due to its
action on MT system, we analyzed a-tubulin PTMs in the corpus
striatum and substantia nigra of mice challenged with MPTP and
chronically treated with EpoD. We observed significant increase of
both Tyr and deTyr tubulin in the striatum of MPTP-treated mice
(Fig. 7a,b), whereas only deTyr tubulin was increased byMPTP in the
substantia nigra (Fig. 7c,d). Furthermore, our data show the ability of
EpoD to restore deTyr tubulin baseline levels, both in striatum
(Fig. 7a,b) and substantia nigra (Fig. 7c,d). The reduction in amarker
of stable MTs, as deTyr tubulin is, induced by a stabilizer drug, as
EpoD is, could seem surprising. However, this is perfectly consistent
with the hypothesis that the increase of stable MTs in MPTP-treated
mice may be an attempt to counteract the drug-induced MT desta-
bilization18. MPP1 is known to promote MT catastrophes16 and, in
respect to dynamic ones, deTyr MTs are more resistant to induced
MT depolymerization; hence, tubulin detyrosination could reduce
MPP1-provoked MT catastrophes. On the other side, as many other
MT-stabilizing agent, EpoD directly induces MT polymerization
under conditions in which tubulin is not more able to assemble,
shifting the equilibrium of tubulin toward the polymeric state. To
verify our hypothesis, we measured the amount of tubulin associated
to cytosolic dimers and to polymericMTs (Fig. 7e,f), both in striatum
and substantia nigra. Our data reveal, for the first time, that MPTP is
able to specifically destabilize MTs in the substantia nigra of treated
mice and that chronic treatment with EpoD prevents the MPTP-
induced destabilization (Fig. 7e,f).
Discussion
Cytoskeletal alterations have been described inmany central nervous
system disorders, but it is unclear whether they are a cause or simply
a by-product of neurodegeneration. Here, we show that systemic
injection of MPTP in mice induces MT dysfunction that occurs very
early, before axonal transport impairment, TH depletion, and,
ultimately, dopaminergic neuron degeneration. Noteworthy is that
chronic administration of the MT stabilizer Epo D rescues MT
defects and is neuroprotective, supplying reliable proof that MT
dysfunction may contribute to actually cause neurodegeneration.
Axonal transport impairment in the MPTP model of PD was first
suggested by Morfini et al. (2007), who proposed that it was an early
event in neurodegeneration, based on the outcome of a study on giant
squid axons. Here we demonstrate that axonal transport impairment
occurs in MPTP-treated mice, showing changes in mitochondria
distribution in dopaminergic fibres. In addition, the earlier decrease
Figure 5 | MPTP affects MT stability in dopaminergic neurons. (a) Immunoblot of levels of tyrosinated tubulin (Tyr Tub), detyrosinated tubulin
(deTyr Tub) and acetylated tubulin (Ac Tub) in lysates of substantia nigra ofmice treated as in Fig. 1. (b) Densitometric analyses of immunoblot reported
in a (mean 6 S.E.M., n 5 4–6 mice per group). For the quantitation, values of each a-tubulin PTMwere normalized on the level of a-tubulin (a Tub) of
the relative sample. *P, 0.05; one-way ANOVA, Dunnett post hoc test versus saline-injected mice. (c) confocal images of substantia nigra ofmice treated
as in Fig. 1. Green represents TH staining and red signals the various tubulin PTMs. Scale bar 5 50 mm. hpi 5 hours post last injection of MPTP.
Table 1 | Analysis of M1 parameter (Tubulins vs. TH) in striatal sections
Tyr Tubulin deTyr Tubulin Ac Tubulin
Saline 0.41 6 0.032 0.30 6 0.025 0.16 6 0.013
MPTP, 30 mg/kg (12 h) 0.27 6 0.021 (*) 0.39 6 0.013 0.28 6 0.028 (*)
MPTP, 30 mg/kg (72 h) 0.27 6 0.048 (*) 0.51 6 0.027 (*) 0.33 6 0.021 (*)
MPTP, 60 mg/kg (12 h) 0.17 6 0.029 (*) 0.34 6 0.034 0.36 6 0.019 (*)
MPTP, 60 mg/kg (72 h) 0.24 6 0.043 (*) 0.32 6 0.030 0.16 6 0.023
Data are expressed as mean 6 S.E.M., n 5 4 sections for each mouse from 4–6 mice per group. *P , 0.05; one-way ANOVA, Dunnett post hoc: versus saline-injected mice.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 1837 | DOI: 10.1038/srep01837 5
in TH in striatum, followed by TH depletion in substantia nigra, can
easily be explained by impairment of axonal transport, other than by
the dying back mechanism of degeneration, typical of PD12 and mice
exposed to MPTP34. Looking for the mechanisms underlying axonal
transport impairment, we found that MPTP does not impact motor
protein levels. However, it affects the levels of deTyr MTs, suggesting
that altered MT stability is responsible for the alterations of axonal
transport. Indeed, Kinesin 1, which is particularly abundant in neu-
rons, is preferentially recruited, but moves slowly along highly
modified MTs33. Furthermore, MPP1 induces increases in deTyr
tubulin content that precede and therefore may cause the reduction
in mitochondrial transport in PC12 cells18. Consequently, we sup-
posed that a similar scenario is likely to occur inMPTP-treated mice.
Nevertheless, another paper by O’Malley’s group26 reported that
MPP1 specifically impairs mitochondria transport in dopaminergic
neurons, an event that precedes autophagy and MT defects. How-
ever, they looked at gross, i.e. Ac-MT fragmentation and a-tubulin
content reduction, rather than at subtle alterations of MTs, such as
Figure 6 | Repeated systemic injections of EpoD attenuate MPTP toxicity in mice. (a) Biochemical analyses of striatal dopamine, DOPAC,
and HVA levels in C57Bl mice injected with MPTP (30 mg/kg, i.p., single injection) alone or in combination with EpoD (1 or 3 mg/kg, i.p.) dissolved in
DMSO and injected 30 min before MPTP. Mice were killed 7 days later (mean 6 S.E.M., n 5 8–10 mice per group). *P , 0.05; one-way ANOVA,
Dunnett post hoc test versus saline-injected mice. (b) Biochemical analyses of striatal dopamine, DOPAC, and HVA levels in C57Bl mice injected with
MPTP (30 mg/kg, i.p., single injection) alone or in combination with EpoD (1 mg/kg, i.p.) dissolved in DMSO and injected 30 min before MPTP and
then for the following 4 days once a day. Mice were killed 7 days later (mean 6 S.E.M., n 5 8–10 mice per group). *, # P , 0.05; one-way ANOVA,
Dunnett post hoc test versus saline-injected mice (*) or versus mice injected with MPTP alone (#). (c) Immunohistochemical analysis of TH in the pars
compacta of substantia nigra of mice injected with a single i.p. injection of 30 mg/kg of MPTP, alone or combined with EpoD (1 mg/kg, i.p.,
30 min prior to MPTP and then for the following 4 days, once a day). Scale bar 5 250 mm. (d) Stereological counts of TH-positive cell in the substantia
nigra pars compacta (mean 6 S.E.M., n 5 5 mice per group). *, # P, 0.05; one-way ANOVA, Dunnett post hoc test versus saline-injected mice (*) or
versus mice injected with MPTP alone (#).
www.nature.com/scientificreports
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changes in PTMs. A further possible cause of the axonal transport
block is MT reorientation, which is induced either by MPP1 18 or by
human mutant Tau expression35 leading to traffic jams. Therefore,
the observed impairment of axonal transport is likely mediated by
alterations of MT stability and organization, which, in turn, lead to
distal axon degeneration, as dying back is, and to the accumulation of
DA loaded vesicles in cell soma. This could really be detrimental to
the neurons since DA oxidation produces large quantities of reactive
oxygen species (ROS) triggering dopaminergic neuron death36.
The observation that levels of the neuron-specific bIII tubulin,
which is the most dynamic among the b-tubulin isotypes37, are
increased points out the importance of MT dynamics and its tight
regulation in MPTP-mediated neurodegeneration, as we have
already shown16,18. bIII tubulin enrichment could be explained as
an adaptive mechanism to counteract the MPTP-induced reduction
in Tyr a2tubulin, usually associated with highly dynamic MTs.
Moreover, bIII tubulin expression is primarily restricted to the nerv-
ous system38, and it has been suggested that different b-tubulin iso-
types could serve specific and unique roles39, such as neuronal
elongation and axon guidance. Banarjee and colleagues40 showed
that in the presence of Tau, a neuron-specific MT binding protein,
bIII tubulin was more prone to polymerize than the other isotypes.
Worthy of note is the recent suggestion that the Tau-MTs interaction
may be important not only in the pathogenesis of Alzheimer’s dis-
ease, but also of PD. Indeed, both MPTP and a-synuclein mutations
promote Tau phosphorylation, causing MT instability, which leads
Figure 7 | EpoD rescues MT system in MPTP-treated mice. (a) Immunoblot of levels of tyrosinated tubulin (Tyr Tub), detyrosinated tubulin
(deTyr Tub) and acetylated tubulin (Ac Tub) in lysates of striatum of mice treated as in Fig. 6. (b) Densitometric analyses of immunoblot reported in a
(mean 6 S.E.M., n 5 5 mice per group). For the quantitation, values of each a-tubulin PTM were normalized on the level of a-tubulin (a Tub) of the
relative sample. *, # P, 0.05; one-way ANOVA, Fischer LSD post hoc test versus saline-injected mice (*) or versus mice injected with MPTP alone (#).
(c) Immunoblot of levels of tyrosinated tubulin (Tyr Tub), detyrosinated tubulin (deTyr Tub) and acetylated tubulin (Ac Tub) in lysates of substantia
nigra of mice treated as in Fig. 6. (d) Densitometric analyses of immunoblot reported in c (mean 6 S.E.M., n 5 5 mice per group). For the quantitation,
values of each a-tubulin PTMwere normalized on the level of a-tubulin (a Tub) of the relative sample. *, # P, 0.05; one-way ANOVA, Fischer LSD post
hoc test versus saline-injected mice (*) or versus mice injected with MPTP alone (#). Tubulin dimers (Dim) and MT polymers (MT) of corpus striatum
and substantia nigra were analyzed by (e) immunoblot and (f) densitometric analyses and are shown as ratio (mean 6 S.E.M., n 5 3 mice per group).
*, # P , 0.05; one-way ANOVA, Fischer LSD post hoc test versus saline-injected mice (*) or versus mice injected with MPTP alone (#).
www.nature.com/scientificreports
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to loss of dopaminergic neurons in PD brain41. Nevertheless, trying
to counteract the ongoing axonal destruction, the dopaminergic neu-
rons could promote MT polymerization through increase in the bIII
tubulin content or in MT stability, as suggested by the enrichment in
deTyr and Ac a-tubulin.
Mitochondria are largely considered crucial players in the patho-
genesis of PD. Indeed, both MPP1 42 and rotenone43 inhibit mito-
chondrial complex I, reducing ATP synthesis and increasing ROS
production. However, the lack of complex I does not protect dopa-
minergic neurons from toxin administration44, suggesting the exist-
ence of alternative mechanisms of action. It is well known that
tubulin interacts with VDAC, the most abundant protein in the
mitochondrial outer membrane, and mitochondria-associated tubu-
lin is enriched in bIII isotype45. Recently, it has been reported that
tubulin decreases the respiration rate of isolated mitochondria46 and
that the increase in tubulin dimers induces mitochondrial depol-
arization in human cancer cells47. Furthermore, the administration
of tubulin-targeted drugs induces mitochondrial depolarization and
Ca11 release48. This body of evidence clearly shows that interfering
with MT system impairs mitochondria activity. Therefore, enrich-
ment in free tubulin dimers in PC12 cells18 and MPTP-induced
increase in bIII tubulin (present data) could induce adverse effects,
such as mitochondrial dysfunction. Being life a matter of balance,
when the equilibrium shifts from a beneficial event, such as MT
polymerization induced by bIII tubulin increases, toward a det-
rimental one, such as mitochondrial dysfunction caused by the same
factor, dopaminergic neurons may die leading to PD. In this context,
it is essential to consider parkin, an E3 ligase promoting degradation
of tubulin and other proteins, known to interact with MTs and to
play a central role in the regulation of mitophagy. Thanks to its
particular position, parkin may quarantine damaged mitochondria,
by severing their connection to the MT network, before promoting
their clearance49. If MT-parkin interaction was impaired, as in the
case of MT destabilization, proper regulation of mitophagy would
fail, leading to dopaminergic neuron loss. Thus, tubulin partitioning
between dimer and polymer pools regulates multiple steps in mito-
chondrial metabolism and, therefore, in the control of neuronal
health and death.
A first step designed to block the progression of the disease would
be the regeneration of collapsing axons. MT stabilization could be
useful to physically counteract axon disruption, reinforcing the pil-
lars that support the structures, and to prevent mitochondrial
damage, reducing the level of free tubulin dimers. In fact, the activa-
tion of signal cascades that converge onMT stability modulation has
trophic effects on axon formation in vivo50,51. It has already been
shown that the MT-stabilizer Taxol protects cultured dopaminergic
neurons against rotenone toxicity17,52, reduces scarring formation
and promotes regeneration of central nervous system axons53,54.
Unfortunately, the blood-brain barrier penetration of Taxol is
very poor55. EpoD, another MT-stabilizing compound, penetrates
through the blood-brain barrier and has resulted to be neuroprotec-
tive in mouse models of schizophrenia56 and tauopathy19. Moreover,
it improves axonal MT density, reduces axonal dystrophy and alle-
viates cognitive deficits in transgenic mouse models of tauopa-
thies19,20. What is more, the dynamicity of MTs is increased in tau
transgenic mice and treatment with EpoD restored MT dynamics.
MT stabilization had beneficial effects on behavior, tau pathology
and neurodegeneration21. Here, we used the classical model of
experimental parkinsonism induced by MPTP to test the hypothesis
that MT stabilization is also able to counteract degeneration in
another model of neurodegeneration. Acute injections of EpoD did
not affect the toxic effect induced by MPTP, whereas repeated injec-
tions of EpoD restored tubulin PTMs andMTmass in the substantia
nigra and exerted neuroprotective effects in the dopaminergic
nigrostriatal system of MPTP-treated mice. Therefore, doses of
EpoD, which were chosen according to Barten and colleagues21, are
also effective in the MPTP model of dopaminergic neurotoxicity.
These data pinpoint that alterations of MTs are very early events,
which specifically occur in dopaminergic neurons in experimental
parkinsonism, and reinforce the idea that the cytoskeleton of dopa-
minergic neurons is particularly vulnerable but is also highly
responsive to MT-targeting agents.
Taken together with our recent findings that MT stability is
impaired in human fibroblasts deriving from PD patients and that
MT stabilization rescues control phenotype28, the present work sug-
gests that MTs are a potential target for pharmacological therapy
designed to block the axonal disruption leading to PD. Thus, chronic
pharmacological stabilization of MT may be a viable strategy for the
management of the disease.
Methods
Materials. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was purchased
from Sigma (St. Louis, MO). Epothilone D was purchased from Acme Bioscience
(Palo Alto, CA).
Animals. Male C57 Black mice (22–24 g, b.w., 8–9 week old) were purchased from
Charles River (Calco, Italy) and used for all experiments. Mice were kept under
environmentally controlled conditions (ambient temperature 5 22uC, humidity 5
40%) on a 12-h light/dark cycle with food and water ad libitum. The study was carried
out in strict accordance with the recommendations in the Guide for the Care and Use
of Laboratory Animals of the National Italian Institute of Health. The protocol was
approved by the Committee on the Ethics of Animal Experiments of the I.R.C.C.S.
Neuromed Institute. Permit Number 432007/A was issued by the Italian Ministry of
Health. All efforts were made to minimize suffering.
Treatments. Mice were treated with one single i.p. injection of 36 mg/kg of MPTP
(corresponding to 30 mg/kg of freeMPTP) or with three doses of 24 mg/kg ofMPTP
hydrochloride (corresponding to 20 mg/kg of free MPTP), injected i.p. at 2 h
intervals (cumulative dose 5 60 mg/kg of free MPTP). Twelve or 72 h after last
injection of MPTP, mice were killed by decapitation or by intracardiac perfusion, to
perform biochemical or immunohistochemical analysis, respectively. One cerebral
hemisphere of mice used for biochemical analysis, was used to evaluate levels of
striatal DA and its metabolites, 3,5-dihydroxyphenylactic acid (DOPAC) and
homovanillic acid (HVA). For EpoD experiments, mice were injected with a single i.p.
dose of 36 mg/kg of MPTP and then acutely (1 or 3 mg/kg, i.p., 30 min prior to
MPTP) or chronically treated (1 mg/kg, i.p., 30 min prior to MPTP and then every
day for 4 days) with EpoD. Mice were killed 7 days later for biochemical analysis of
MTs and biochemical and immunohistochemical assessment of nigro-striatal
damage. EpoDwas dissolved inDMSO and injected i.p. (in a volume of 50 ml/mouse).
Control mice were injected with the vehicle alone.
Motor activity assessment.Motor coordination was assessed by the rotarod test. The
rotarod apparatus consisted of a motor driver control unit (Ugo Basile, Varese, Italy)
and a rotating horizontal cylinder (30 mm), divided into five separate rotating
compartments and fully enclosed to ensure that the mice did not jump out of their
area. Automatic timers recorded the time (in seconds) the mice remained on the rod,
which was rotating at an accelerating speed from 5 to 15 rpm. Mice were tested for
10 min on the rotarod every day, starting 2 days after MPTP or EpoD injection (as
above). General health conditions (fur, body weight and mortality) were also
monitored by an experimenter unaware of treatments.
Monoamine assay.The corpus striatumwas immediately dissected out homogenized
by sonication in 0.6 ml of ice-cold 0.1 M PCA. Fifty ml of the homogenate were used
for protein determination57. The remaining aliquot was centrifuged at 8,000 g for
10 min, and 20 ml of the supernatant was injected into an HPLC equipped with
autosampler 507 (Beckman Instruments, Fullerton, CA), a programmable solvent
module 126 (Beckman), an analytical C-18 reverse-phase column kept at 30uC
(Ultrasphere ODS 5 mm, 80 A˚ pore, 250 3 4.6 mm (Beckman), and a Coulochem II
electrochemical detector (ESA, Inc., Chelmsford, MA). The holding potentials were
set at 1350 and 2350 mV for the detection of DA, DOPAC and HVA. The mobile
phase consisted of 80 mM sodium phosphate, 40 mM citric acid, 0.4 mM EDTA,
3 mM 1-heptansulphonic acid and 8.5% methanol, brought to pH 2.75 with
phosphoric acid (run under isocratic conditions, at 1 ml/min).
Western blot analysis. Western blot analysis was performed on protein extracts or
cytoskeletal fractions obtained from mouse brain regions. To get total proteins,
corpus striatum and substantia nigra were immediately dissected out on ice,
mechanically homogenized and, subsequently, sonicated in SDS-PAGE sample
buffer. Separation of cytosolic tubulin dimers from MT polymers was performed
accordingly to Fanara and colleagues58. Briefly, corpus striatum and substantia nigra
were gently homogenized in MT-stabilizing buffer and postnuclear supernatants
were centrifuged at 200,000 g at 20uC for 20 min; the supernatant (containing the
soluble dimeric tubulin) and the pellet (containing the MT fraction) were separated
and stored at 220uC. Western blots were made as previously described18 using the
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following antibodies: a-tubulin mouse IgG (clone B-5-1-2, Sigma-Aldrich); deTyr
tubulin rabbit IgG (Chemicon, Temecula, CA); Tyr tubulin mouse IgG (clone TUB-
1A2, Sigma-Aldrich); Ac tubulin mouse IgG (clone 6-11B-1, Sigma-Aldrich); b-
tubulin mouse IgG (clone Tub 2.1, Sigma-Aldrich); bIII tubulin mouse IgG (clone
TU-20, kindly provided by Dr. Pavel Dra`ber, Prague, Czec Republic); actin mouse
IgM (N350, Amersham, Little Chalfont, UK); tyrosine hydroxylase (TH) mouse IgG
(clone 6dt, Abcam, Cambride, UK) 15600; kinesin rabbit IgG (Abcam) 151000;
Dynein mouse IgG (clone 74.1, Millipore) 15500, GAPDH (Abcam). Membranes
were washed for 30 min with 3 changes and incubated for 1 h at room temperature
with HRP donkey anti-mouse IgG (Pierce), HRP goat anti-mouse IgM (Sigma-
Aldrich), or HRP goat anti-rabbit IgG (Pierce). Immunostaining was revealed by
enhanced chemiluminescence (Super-Signal West Pico Chemiluminescent, Pierce).
Quantification was performed by ImageJ software (NIH, Bethesda, MD).
Confocal analysis.Mice were anesthetized with chloralium hydrate (320 mg/kg, i.p.)
and transcardially perfused with 4% PFA in 0.1 M phosphate buffer, pH 7.4. Brains
were removed, postfixed overnight in 4% PFA, and then transferred in 30% sucrose
for cryoprotection. Sagittal sections (50 mm thick) were cut with a Vibratome
(VT1000S, Leica). Sections were stained with porin rabbit IgG (VDAC1/porin,
Abcam, Cambride, UK) and the following antibodies previously used for
immmunoblotting: deTyr tubulin rabbit IgG; Tyr tubulin mouse IgG; Ac tubulin
mouse IgG; porin rabbit IgG (VDAC1/porin, Abcam). To identify dopaminergic
neurons and fibres, each section was concurrently stained with anti-TH antibody,
made in mice (clone LCN1, Millipore) or rabbits (Millipore) as appropriate. As
secondary antibodies we used Alexa FluorTM 568 donkey anti-mouse IgG, and Alexa
FluorTM 488 goat anti-rabbit IgG (Invitrogen). Coverslips were mounted in PBS-
glycerol and examined with a confocal laser scan microscope imaging system (TCS
SP2 AOBS, Leica Microsystems, Heidelberg, Germany) equipped with an Ar/Ar-Kr
488 nm, 561 nm and 405 nm diode lasers. Photomultiplier gain for each channel was
adjusted to minimize background noise and saturated pixels and, once defined for
control conditions, parameters were kept constant for all acquisitions. To estimate the
overlapping area between red and green signals, analyses were carried out on single-
plane raw images andManders’ coefficients were calculated applying the JACoP plug-
in (developed and reviewed by 31) for ImageJ software. To evaluate the mitochondria
distribution, the porin signal was superimposed on dopaminergic fibres, using the
Mask tool of the Leica Confocal Software (Leica); mitochondria accumulations were
identified as white pixels-containing area, as thick as long, clearly separated from
other white pixels. TH-positive signal longer than 5 mm was considered as
dopaminergic fibre, and signals separated by more than 10 mm were counted as two
distinct fibres.
Immunohistochemical analysis of tyrosine hydroxylase. Brains were removed,
fixed in ethanol (60%), acetic acid (10%), and chloroform (30%), and included in
paraffin. Tissue sections (30 mm) were incubated overnight with monoclonal mouse
anti-TH (15200; Sigma-Aldrich) and then for 1 h with secondary biotin-coupled
anti-mouse antibodies (15200; Vector Laboratories, Burlingame, CA). 3,3-
Diaminobenzidine tetrachloride (Sigma) was used for detection.
Stereological cell counting of tyrosine hydroxylase-positive cells in the substantia
nigra pars compacta. The number of TH-positive cells in the substantia nigra pars
compacta was assessed by stereological technique and an optical fractionator using a
Zeiss Axio ImagerM1microscope equipped with amotorized stage and focus control
system (Zeta axis), and with a digital video camera. The software Image-Pro Plus 6.2
for Windows (Media Cybernetics, Inc., Bethesda, MD) equipped with a Macro was
used for the analysis of digital images. The Macro was obtained by ‘‘Immagini e
Computer’’ (Bareggio, Italy). The characteristics of this Macro are published59. The
analysis was performed on 6 sections of 20 mm, sampled every 200 mmon the rostro-
caudal extension, in which the substantia nigra was identified and outlined at 2.53
magnification. TH-positive cells were counted at 1003 magnification as described60.
For stereological analysis, we used a grid of disectors (counting frame of 100 3
100 mm; grid size 50 3 50 mm), with 1.3 as numerical aperture of the lens. The total
number of TH-positive cells in the substantia nigra was computed from the formula:
N 5S(n) 3 1/SSF 3 1/ASF 3 1/TSF, where n is the total number of cells counted on
each disector; SSF (fraction of sections sampled) the number of regularly spaced
sections used for counts divided by the total number of sections across the substantia
nigra pars compacta; ASF (area sampling frequency) the disector area divided by the
area between disectors (7500 mm2 3 disector number/region area); and TSF
(thickness sampling frequency) the disector thickness divided by the section thickness
(20 mm).
Statistical analysis and data managing. The statistical significance of treatment was
assessed by one-way ANOVA with Dunnett 2-sided or Fischer LSD post-hoc testing
or x2 test when appropriate. Analyses were performed using STATISTICA (StatSoft
Inc., Tulsa, OK).
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